Recent

% | $
Quotes you view appear here for quick access.

Medivation, Inc. Message Board

  • biofutures biofutures Feb 20, 2013 11:43 AM Flag

    PREVAIL phase 3 study results approaching on the horizon...

    Xtandi's PREVAIL study design for chemo-naive prostate cancer gives patients the option to remain on Xtandi despite disease progression, while for Zytiga's 302 study patients had to discontinue use upon disease progression. The Xtandi AFFIRM study in post-chemo and the phase 1/2 study published in the Lancet, indicate that Xtandi is more potent than Zytiga, and given the better trial design in the PREVAIL study, the length of Xtandi therapy should be longer than Zytiga's. In the Zytiga 302 study, the median duration of Zytiga therapy was 15 months.

    According to Citibank's initial modeling of Xtandi, they estimated 12 months of therapy for the PREVAIL trial... and Citibank notes that every 1 month of extra duration of therapy increases their target price by $16 pps.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MDVN
59.22+0.16(+0.27%)May 5 4:00 PMEDT